A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Completed · Phase 3 · NCT04435600
Conditions: Psoriasis
At a glance
- Research payments reported, 2025
- $85,380
- U.S. investigators named
- 8
- Sites paid
- 8
- Planned or actual enrollment
- 139
About the trial
- Sponsor
- AbbVie
- Tested
- Risankizumab (drug), Ustekinumab (drug)
- Dates
- Started 2020-07-14; completion 2024-10-15
- Results posted
- Yes
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There is an unmet medical need for effective treatment in pediatric patients and this study is being done to evaluate risankizumab in pediatric participants with moderate to severe plaque psoriasis. This study will assess the change in disease symptoms. Risankizumab is a drug being studied for the treatment for plaque psoriasis in pediatric participants. This study has 4 parts. Part 1: Participants aged 12 \< 18 will receive a fixed dose of risankizumab. Part 2: Participants aged 12 \< 18 will receive; * Period A: Risankizumab or ustekinumab based…
From ClinicalTrials.gov, last updated 2025-05-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $85,380 in research payments for this study in 2025 (17 payments).
Products named: Skyrizi
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Boni Elewski Dermatology · Birmingham, AL
- Vivian Laquer, M.D. Dermatology · Irvine, CA
- Raja Sivamani, M.D., M.S., A.H.E. Dermatology · Sacramento, CA
- Francis A. Caban, M.D. Dermatology · Brandon, FL
- Matthew B. Zook, MD, PHD Dermatology · St Petersburg, FL
- Lara Wine Lee, M.D. Dermatology · Charleston, SC
- Kristen E. Holland, MD Dermatology · Milwaukee, WI
- Zachary A. Zinn, M.D. Dermatology · Morgantown, WV
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- First Oc Dermatolgy Research Inc $21,302
- Caban Health LLC $13,850
- University of Alabama Hospital, AL $12,610
- West Virginia University $12,161
- Medical University of South Carolina $11,730
- Integrative Skin Science & Research $9,698
- Academic Alliance in Dermatology $2,500
- Medical College of Wisconsin $1,530
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.